Dr. Mitchell deLong

Vice President, Chemistry R&D
Aerie Pharmaceuticals

The Discovery of Netarsudil, the First FDA-approved ROCK Inhibitor for the Treatment of Glaucoma

In December, 2017, Netarsudil became the first compound in the first new class of glaucoma drugs to be FDA-approved since 1996. Aerie Pharmaceuticals is a small biotech spin-out of Duke University, based in Durham, North Carolina, with offices in Irvine. This lecture covers Aerie Pharmaceuticals experience through the discovery, synthesis, pharmacology, scale up, clinical trials and FDA-approval of this amino-isoquinolyl amide, and the journey of bringing a novel rho kinase inhibitor to market where many others had tried and failed.

Hosted by Professor Travis Williams

The scientific community is invited